
FDA Proposes Shifting Blue Light Cystoscopy Systems to Class II
The U.S. Food and Drug Administration has initiated a move to reclassify blue light cystoscopy systems from Class III to Class II, signaling a shift in how the agency regulates diagnostic tools used for bladder cancer detection after reviewing decades of clinical evidence and post-market safety data.
























